Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 252
- Registration Number
- NCT02185014
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 358
- Registration Number
- NCT02171429
- Locations
- 🇧🇬
Medical center Medconsult Pleven OOD, Pleven, Bulgaria
🇦🇷Centro de Investigaciones Medicas Mar Del Plata, Mar del Plata, Argentina
🇧🇬DCC Sv. Pantaleymon OOD, Pleven, Bulgaria
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 358
- Registration Number
- NCT02163759
- Locations
- 🇵🇱
EMC Instytut Medyczny S.A., Wrocław, Poland
🇵🇱AppleTreeClinics Sp. z o.o., Łódź, Poland
🇪🇪Tartu University Hospital, Tartu, Estonia
The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 21
- Registration Number
- NCT02150473
- Locations
- 🇩🇪
Universitätsklinikum Düsseldorf, Düsseldorf, NRW, Germany
Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Jagiellonian University
- Target Recruit Count
- 100
- Registration Number
- NCT02132234
- Locations
- 🇵🇱
Katedra Chorób Wewnętrznych i Medycyny Wsi, Uniwersytet Jagielloński, Krakow, Skarbowa 4, Poland
Clinical Trial Using Humira in Netherton Syndrome
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 11
- Registration Number
- NCT02113904
- Locations
- 🇫🇷
Necker Enfants Malades hospital, Paris, France
A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT02097264
Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
- Conditions
- Interventions
- First Posted Date
- 2014-03-20
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 198
- Registration Number
- NCT02092961
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 514
- Registration Number
- NCT02065570
- Locations
- 🇺🇸
Texas Digestive Disease Consultants - Dallas /ID# 138121, Dallas, Texas, United States
🇺🇸University of Chicago DCAM /ID# 119077, Chicago, Illinois, United States
🇺🇸Atlanta Gastro Assoc /ID# 119065, Atlanta, Georgia, United States
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 952
- Registration Number
- NCT02065622
- Locations
- 🇺🇸
Atlanta Gastro Assoc /ID# 122336, Atlanta, Georgia, United States
🇺🇸Northwestern University Feinberg School of Medicine /ID# 122183, Chicago, Illinois, United States
🇺🇸University of Pittsburgh MC /ID# 122331, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.